The importance of a strong collection cell collection network during the COVID-19 pandemic

Cell & Gene Therapy Insights 2020; 7(1), 21.

10.18609/cgti.2021.046

Published: 11 February 2021
FastFacts
Chris McClain, MBA


Watch the video or read the poster to learn:

  • Why strong collection networks are key in the cell and gene therapy space
  • How COVID-19 is introducing new challenges for cell collection
  • Lessons learned from managing large-scale cell collection networks before and during the pandemic

About the speaker

Senior Vice President, Sales and Business Development Be The Match BioTherapies®

Chris McClain, MBA the sales and business development team, which engages with companies developing innovative, lifesaving therapies that can leverage the cell sourcing, cell therapy supply chain, CRO services, and outcomes tracking capabilities of the National Marrow Donor Program and Be The Match. Before joining Be the Match BioTherapies full-time, Chris was co-Founder of Nora Therapeutics, a venture-backed biopharmaceutical company developing novel therapies in areas of significant unmet medical need in reproductive health. While at Nora Therapeutics, Chris and his team raised more than $50 million in venture capital to fund pre-clinical and clinical development of Nora’s lead asset and build out a world-class executive team.